They already knew they had a winner. Now, RepRegen has more confirmation…the company has announced that its Chief Science Officer, Molly Stevens, Ph.D., has been named one of the top-10 most important scientists under the age of 40 in Britain by The Times’ Eureka 100.
Molly Stevens, Ph.D. in Top 10 Scientists
2 min read Premium comments
In addition to her role as CSO for RepRegen, Dr. Stevens is Professor of Biomedical Materials and Regenerative Medicine and Research Director for Biomedical Material Sciences at the Institute of Biomedical Engineering, Imperial College London. She joined Imperial in 2004 after spending several years as a Postdoctoral Associate working in the field of tissue-engineering with renowned Professor Robert Langer in the Chemical Engineering Department at the Massachusetts Institute of Technology (MIT). In 2005 she received the prestigious Philip Leverhulme Prize. She has also been recognized (2004) by the Technology Review 100, a compilation of the top innovators, under 35, who are transforming technology. Her previous awards include the Ronald Belcher Memorial Lecture Award from the Royal Society of Chemistry (2000) and both the Janssen Prize and UpJohn Prize for academic excellence and research.
“We are extremely happy for Molly and very pleased with the significant work she has done in designing our platform to dramatically upgrade the repair and regeneration of hard tissue such as bone, ” said Ian Brown, RepRegen’s CEO, in the news release. “Molly is a brilliant pragmatist.”
“Molly Stevens is certainly one of the leading scientists of her generation, ” added Stephen Rietiker, M.D., Chairman of RepRegen, “not only because she’s a genius at tissue-engineering, but also because her inventions are designed specifically to solve big problems in the real world.”
Dr. Stevens told OTW,
My research focuses on the development of new biomaterials for regenerative medicine and biosensing applications. The RepRegen platform includes novel bioceramic-based materials that have a dual effect on both osteoblasts and osteoclasts. This enables them to be highly effective in bone repair applications. We are also developing composite materials with tailored chemical and mechanical properties for use in osteochondral repair.
She added, “We are also engineering new biomaterials that can be used in other applications. For example, we are also developing injectable gels for use in the heart after myocardial infarction.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.